Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Chapman, Paul B., Hauschild, Axel, Robert, Caroline, Haanen, John B., Ascierto, Paolo, Larkin, James, Dummer, Reinhard, Garbe, Claus, Testori, Alessandro, Maio, Michele, Hogg, David, Lorigan, Paul, Lebbe, Celeste, Jouary, Thomas, Schadendorf, Dirk, Ribas, Antoni, O’Day, Steven J., Sosman, Jeffrey A., Kirkwood, John M., Eggermont, Alexander M.M., Dreno, Brigitte, Nolop, Keith, Li, Jiang, Nelson, Betty, Hou, Jeannie, Lee, Richard J., Flaherty, Keith T., McArthur, Grant A.
格式: Artigo
語言:Inglês
出版: 2011
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549296/
https://ncbi.nlm.nih.gov/pubmed/21639808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1103782
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍